Pricing Log in Create free account
Saturday 17 October 2026 Export ARDX’s income statement to Excel — free account

Ardelyx, Inc.

ARDX Healthcare Biotechnology

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%
Market cap
$814.9M
P/E
0.0×
Fwd P/E
−122×
Dividend yield
—
F-score
2/9
Altman Z
1.12
Beneish M
−2.40
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.95
Total sells 4.30
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — 1 — — — — — — — —
Sell 6 — 1 9 1 1 9 2 1 8 — —
Insider Ownership 3.48%

Capital & Financial Ratios $m

Market Cap 814.85
Revenue 450.89
Net Income (55.70)
Free Cash Flow (17.92)
Net Debt (30.01)
Current Ratio 3.34 (at or above 1.5: strong)
Debt/Equity 1.69
P/E ratio 0.00
Fwd P/E (122.00) (negative: loss-making)
P/S ratio 1.70
P/B ratio 5.14
Past 5Y EPS Growth —
This Y EPS Growth 29.55% (at or above 15%: strong)
Next Y EPS Growth 238.33% (at or above 15%: strong)
Next Y revenue growth 19.98% (at or above 10%: strong)
Next 5Y EPS Growth 30.00% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.7×, against a ten-year median of 7.3×; over the ten years it ranged from −7.0× in 2018 to 462× in 2019.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 62.59%
10-year low 10-year high
EV/Sales against its own 10 years 2.87%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 184 250 265 282
Receivables 22 58 72 100
Inventory 12 21 18 26
Other — — — —
246 356 382 442
2023 2024 2025 Q'26
Payables 11 16 19 38
ST’ Debt — — — —
Other 15 35 48 71
50 78 89 132

Compound Annual Growth %

10y 5y 3y
Sales 29.12% 121.90% 98.40%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 4.37% 5.77% 19.30%

Revenue $m

Mar Jun Sep Dec Year
’26 94 121 — — —
’25 74 98 110 125 407
’24 46 73 98 116 334
’23 11 22 56 34 124
’22 0 3 5 44 52
’21 7 1 1 1 10
’20 1 2 3 2 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (32) (6) — — —
’25 (38) (25) 0 21 (42)
’24 (36) (19) 1 10 (45)
’23 (45) (15) (21) (9) (90)
’22 (28) (31) (25) 14 (70)
’21 (44) (34) (35) (39) (153)
’20 (25) (19) (20) (18) (81)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (32) (6) — — —
’25 (39) (26) 0 21 (44)
’24 (36) (20) 0 9 (46)
’23 (45) (15) (22) (9) (90)
’22 (27) (31) (25) 14 (68)
’21 (45) (35) (35) (39) (154)
’20 (25) (19) (20) (18) (82)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.15) (0.07) — — —
’25 (0.17) (0.08) 0.00 0.00 (0.26)
’24 (0.11) (0.07) 0.00 0.02 (0.17)
’23 (0.13) (0.08) 0.03 (0.12) (0.30)
’22 (0.21) (0.19) (0.14) 0.06 (0.42)
’21 (0.34) (0.45) (0.42) (0.31) (1.52)
’20 (0.25) (0.28) (0.20) (0.32) (1.05)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 6.36 4.05 1.60 1.70 4.22 0.82 0.49 2.63 4.32 3.21

Analyst estimates 2026–2028

Powerpack
High 17.90 15.40 8.10 8.49 8.82 9.23 2.86 6.75 10.13 6.78
People
People Employees 93 75 86 88 129 86 133 267 395 489
Revenue/emp, $m 0.00 0.56 0.03 0.06 0.06 0.12 0.39 0.47 0.84 0.83
Income, $m
Income, $m Revenue — 42 3 5 8 10 52 124 334 407
Gross margin, % 0.00 80.00 82.13 88.64 98.08 90.10 92.11 85.70 84.85 90.29
EBT (112) (63) (91) (95) (94) (158) (67) (66) (39) (61)
EBT margin, % 0.00 (150.38) (3,501.88) (1,792.03) (1,245.69) (1,566.42) (128.84) (52.65) (11.65) (14.89)
Net income (112) (64) (91) (95) (94) (158) (67) (66) (39) (62)
Depreciation 2 3 2 3 3 3 1 1 2 3
Per share, $
Per share, $ Revenue 0.00 0.89 0.05 0.08 0.08 0.10 0.33 0.57 1.42 1.69
Earnings (2.80) (1.36) (1.62) (1.47) (1.05) (1.52) (0.42) (0.30) (0.17) (0.26)
Cash flow (2.31) (1.37) (1.25) (1.19) (0.91) (1.46) (0.44) (0.41) (0.19) (0.18)
Capex (0.12) (0.05) (0.01) 0.00 0.00 (0.02) 0.01 0.00 0.00 (0.01)
Free cash flow (2.43) (1.42) (1.26) (1.19) (0.91) (1.48) (0.43) (0.41) (0.19) (0.18)
Book value 4.81 2.94 2.06 2.89 1.41 0.79 0.62 0.76 0.74 0.69
Shares, m 40 47 56 64 90 104 159 219 235 241
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 10.94 38.60 90.24 76.55 11.35 8.15 10.66 3.57 3.45
P/B — 2.38 0.87 2.59 4.60 1.39 4.33 7.95 6.88 8.42
EV/Sales — 6.52 (7.00) 53.44 58.63 3.96 6.62 9.80 3.36 3.36
EV/FCF — (2.93) 0.26 (3.73) (5.43) (0.26) (5.05) (13.54) (24.45) (31.16)
Cash, $m
Cash, $m Operating cash flow (93) (65) (70) (76) (81) (153) (70) (90) (45) (42)
Capex (5) (2) 0 0 0 (2) 2 0 (1) (1)
Free cash flow (97) (68) (71) (77) (82) (154) (68) (90) (46) (44)
Balance, $m
Balance, $m Working capital 185 132 159 230 166 81 88 196 279 294
Total debt — — 49 50 51 42 44 50 151 203
Net debt (201) (134) (119) (197) (136) (75) (80) (134) (99) (62)
Shareholders’ equity 193 139 116 187 126 83 98 167 173 167
Returns, %
Returns, % ROA (68.10) (34.68) (53.51) (42.85) (40.89) (90.00) (39.54) (27.10) (10.67) (13.14)
ROIC 0.00 (762.69) 0.00 0.00 0.00 (1,214.94) (218.47) (122.29) (23.59) (24.37)
ROE (74.42) (38.70) (71.57) (62.78) (60.31) (151.55) (74.28) (49.83) (23.01) (36.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Ardelyx, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
KURA Kura Oncology, Inc. $862.9M — (loss-making) — (loss-making) +36.54% (above 0%: growing) n/m −109.05% (below 0%: shrinking) 98.84% (349.77%) Compare
ALMS Alumis Inc. $842.4M — (loss-making) — (loss-making) −37.66% (below 0%: shrinking) n/m +23.59% (above 0%: growing) 100.00% (8,956.38%) Compare
VSTM Verastem, Inc. $835.9M — (loss-making) — (loss-making) +1,775.43% (above 0%: growing) n/m −34.43% (below 0%: shrinking) 89.92% (81.62%) Compare
CRVS Corvus Pharmaceuticals, Inc. $828.6M — (loss-making) — — n/m −171.31% (below 0%: shrinking) 0.00% 0.00% Compare
AVBP ArriVent BioPharma, Inc. $827.9M — (loss-making) — — n/m −51.51% (below 0%: shrinking) — 0.00% Compare
ARDX Ardelyx, Inc. $814.9M — (loss-making) — (loss-making) +23.77% (above 0%: growing) n/m +75.33% (above 0%: growing) 95.24% (10.28%)
HELP Cybin Inc. $807.3M — (loss-making) — (loss-making) — n/m −25.60% (below 0%: shrinking) 0.00% 0.00% Compare
DNA Ginkgo Bioworks Holdings, Inc. $791.9M — (loss-making) — (loss-making) −48.49% (below 0%: shrinking) n/m −16.38% (below 0%: shrinking) 91.47% (290.47%) Compare
GERN Geron Corporation $790.2M — (loss-making) — (loss-making) +17.22% (above 0%: growing) n/m +41.82% (above 0%: growing) 83.92% (21.74%) Compare
Median of peers $828.2M — — +17.22% — −30.02% 89.92% (51.68%)

All 614 Biotechnology stocks →

Ardelyx, Inc. (ARDX) key facts

  • Strength: Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
  • Ardelyx, Inc. (ARDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ARDX traded at $3.09, a market capitalization of $814.9 million.
  • Return on equity was −36.2% and debt-to-equity 1.69.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Ardelyx, Inc. (ARDX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ARDX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com